Sterically stabilized gelatin microassemblies of noscapine enhance cytotoxicity, apoptosis and drug delivery in lung cancer cells

Madan, Jitender; Pandey, Ravi Shankar; Jain, Upendra Kumar; Katare, Om Prakash; Aneja, Ritu; Katyal, Anju

doi:10.1016/j.colsurfb.2013.02.010

Cited by 47 publications

(35 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In light of its tremendous potential for controlled release, gelatin has been extensively investigated as a delivery vehicle for many classes of drugs, including but not limited to antibacterial agents [25, 26], anti-inflammatory drugs [27, 28], and many different antineoplastic compounds [17, 19, 29, 30]. Regardless of the specific application, gelatin carriers demonstrate reduced side effects when compared to the administration of the free compound, with improved pharmacokinetic profile and drug efficacy [9].…”

Section: Modification Of Gelatinmentioning

confidence: 99%

“…As such, chemical motifs have been introduced to the flexible aminoacidic structure of gelatin in order to ensure high encapsulation efficiency and the desired release of these drugs [33]. Modification of gelatin follows three strategies: (i) the synthesis of stealth carriers to increase drug bioavailability [17], (ii) the enhancement of drug encapsulation efficiency [34], and (iii) the conjugation of gelatin with dedicated biomolecules for targeted drug delivery [35] (Table 1). …”

Section: Modification Of Gelatinmentioning

confidence: 99%

“…It is widely recognized that drug delivery carriers (especially at the micro- to nano-scale) are rapidly identified and phagocytized by the reticuloendothelial system, depending on their physicochemical properties such as particle size, hydrophobicity and zeta potential [17]. The modification of gelatin with poly(ethylene glycol) (PEG), termed PEGylation, is currently the leading strategy for the fabrication of stealth drug delivery systems, with slower clearance from the body and prolonged circulatory time [43].…”

Section: Modification Of Gelatinmentioning

confidence: 99%

“…In addition, release kinetics from gelatin depends on carrier degradation, which can be tuned by either varying gelatin molecular weight or the extent of material crosslinking [2]. Accordingly, drug loading and release kinetics can be independently optimized, making gelatin an exceptionally adaptable drug delivery carrier as witnessed by the broad range of applications in which it has been used: tissue engineering [14–16], cancer therapy [17–19], and therapeutic angiogenesis [20–22]. …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Gelatin carriers for drug and cell delivery in tissue engineering

Santoro

Tatara

Mikos

2014

Journal of Controlled Release

323

202

View full text Add to dashboard Cite

The ability of gelatin to form complexes with different drugs has been investigated for controlled release applications. Gelatin parameters, such as crosslinking density and isoelectric point, have been tuned in order to optimize gelatin degradation and drug delivery kinetics. In recent years, focus has shifted away from the use of gelatin in isolation towards the modification of gelatin with functional groups and the fabrication of material composites with embedded gelatin carriers. In this review, we highlight some of the latest work being performed in these areas and comment on trends in the field. Specifically, we discuss gelatin modifications for immune system evasion, drug stabilization, and targeted delivery, as well as gelatin composite systems based on ceramics, naturally-occurring polymers, and synthetic polymers.

show abstract

Section: Modification Of Gelatinmentioning

confidence: 99%

Section: Modification Of Gelatinmentioning

confidence: 99%

Section: Modification Of Gelatinmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Gelatin carriers for drug and cell delivery in tissue engineering

Santoro

Tatara

Mikos

2014

Journal of Controlled Release

323

202

View full text Add to dashboard Cite

show abstract

“…Our laboratory is actively engaged in the design and development of anticancer nanotherapeutics for tumour targeting [11][12][13][14][15][16][17][18][19][20]. Microspheres can maintain adequate serum concentration for a long period of time, prevent degradation and increase the therapeutic index and half-life of drugs [4,5,10,21].…”

Section: Introductionmentioning

confidence: 99%

Sustained-release protamine sulphate-impregnated microspheres may reduce the frequent administration of recombinant interferon α-2b in ovarian cancer

Gulia

Rai²,

Jain³

et al. 2014

Anti-Cancer Drugs

Self Cite

View full text Add to dashboard Cite

Parenteral administration of recombinant interferon-α-2b (rINF-α-2b) at a dose of 50×10 IU once a week for 8 weeks is recommended for ovarian cancer. However, short half-life, small therapeutic index and proteolytic degradation cause fluctuations in plasma level and pose barriers in the development of a clinically viable dosage form. Therefore, in the present investigation, fluorescein isothiocynate-tagged rINF-α-2b was loaded into stearic acid (*rINF-α-2b-SMs), pectin (*rINF-α-2b-PMs) and gelatin (*rINF-α-2b-GMs) microspheres. Parameters such as particle size, ζ potential, encapsulation efficiency and in-vitro release were studied to follow the optimization process. The formulation, *rINF-α-2b-GMs of particle size 8.3±2.1 μm with an encapsulation efficiency of 76.0±7.4%, offered 97.4% of *rINF-α-2b release at 288 h. Thus, negatively charged extended-release formulation *rINF-α-2b-GMs was then tethered with a gradient concentration (5-20 mg/ml) of a cationic arginine-rich protein stabilizer, protamine sulphate (Pt). The nanoformulation, *rINF-α-2b-Pt-GMs-15 superimposed with 15 mg/ml of Pt, released 95.0% of *rINF-α-2b at 336 h and was designated as the optimized formulation. The optimized formulation also conserved the primary and secondary structure of *rINF-α-2b as analysed by gel electrophoresis and circular dichroism. Moreover, in-vitro cytotoxicity analysis of SKOV3 cells of the optimized nanoformulation reported significantly (one-way analysis of variance test, P<0.05) lower IC50 (414.3 IU/ml) compared with *rINF-α-2b-GMs (514.3 IU/ml) and pure rINF-α-2b (628.6 IU/ml) at 72 h by offering a prolonged cytotoxic effect. Therefore, *rINF-α-2b-Pt-GMs-15, a promising nanomedicine, warrants further in-depth in-vivo study to scale up the technology for clinical translation.

show abstract

Self‐assembled poly(ethylene glycol) methyl ether‐grafted gelatin nanogels for efficient delivery of curcumin in cancer treatment

Tran

Nguyen

et al. 2019

J of Applied Polymer Sci

View full text Add to dashboard Cite

Curcumin (CUR) is a natural active ingredient that attracted much attention for its chemotherapeutic activity against tumors without causing toxicity in healthy cells. However, it has certain limitations for being used in chemotherapy such as low aqueous solubility and hydrolytic instability in the physiological environment. In this study, self-assembled poly(ethylene glycol) methyl ether-grafted gelatin (Gel-mPEG) nanogels were fabricated as delivery systems to improve the applicability of CUR in cancer treatment. CUR-loaded Gel-mPEG nanogels exhibited desired size range, relatively colloidal stability, and provided enhanced CUR stability in aqueous solutions. Especially, they showed significant high CUR loading capacity and better anticancer activity than free CUR as compared to previously reported CUR-loaded nanogels according to the best of our knowledge. Moreover, the in vitro release of CUR from the nanogels was controlled and prolonged up to 96 h. These results demonstrated that Gel-mPEG nanogels are the promising modality for the efficient delivery of CUR in cancer treatment.

show abstract

Sterically stabilized gelatin microassemblies of noscapine enhance cytotoxicity, apoptosis and drug delivery in lung cancer cells

Cited by 47 publications

References 36 publications

Gelatin carriers for drug and cell delivery in tissue engineering

Gelatin carriers for drug and cell delivery in tissue engineering

Sustained-release protamine sulphate-impregnated microspheres may reduce the frequent administration of recombinant interferon α-2b in ovarian cancer

Self‐assembled poly(ethylene glycol) methyl ether‐grafted gelatin nanogels for efficient delivery of curcumin in cancer treatment

Contact Info

Product

Resources

About